## Business Summary

InMode Ltd. operates primarily on a "razor and blade" business model within the aesthetic medical device industry. The company manufactures and sells high-priced, advanced radiofrequency technology platforms (the "razors") to medical professionals, including plastic surgeons, dermatologists, and medical spas, mainly located in North America but expanding globally. The core business profitability is driven by the consistent sale of disposable components, handpieces, and treatment tips (the "blades"). These consumables must be continuously repurchased by the clinical customers to perform procedures like skin tightening and body contouring, ensuring a high-margin, recurring revenue stream for the company.

---

## Business Model Risk

The primary risk stems from the business model’s dependence on elective procedures. If the economy suffers a near-term downturn, consumers often cut back on non-essential spending, leading medical practices to reduce their purchases of both expensive new capital equipment and the recurring disposable consumables. A significant long-term risk is intense competition and technological obsolescence; rival companies are constantly innovating, and if a competitor releases a superior technology that does not require expensive disposables, InMode's crucial recurring revenue base could be severely harmed. This sector has historically proven highly vulnerable during periods of economic recession and unforeseen external shocks, such as the halting of elective surgeries during the initial phase of the COVID-19 pandemic, making reduced consumer spending a perpetual concern for their earnings.

---

## Company History

This is a history lesson on InMode Ltd. (NASDAQ: INMD), a company that reshaped a part of the cosmetic and medical industry.

---

### **The History of InMode Ltd. (INMD): From Founding to Present**

#### **I. Inception and Founding Mission (2008 - 2016)**

1.  **Founding and Founders:** InMode was founded in 2008 in Yokneam, Israel, initially under the name Invasix Ltd., which it later changed in 2017. The company was co-founded by Moshe Mizrahy (CEO) and Dr. Michael Kreindel (CTO), who were already veterans in the medical aesthetic device industry, having previously co-founded a major competitor.

2.  **The Business Goal (The "Treatment Gap"):** The entire business was founded to solve a major problem known as the **"Treatment Gap."** This gap existed between two extremes:
    *   **Non-invasive treatments:** Procedures like basic laser or superficial radiofrequency that had little or no downtime but were often not very effective.
    *   **Traditional Surgery:** Procedures like a tummy tuck or facelift that provided dramatic results but required general anesthesia, large scars, and a long, painful recovery.

3.  **The Core Innovation (Minimally-Invasive RF):** InMode's solution was to use sophisticated, proprietary **Radio-Frequency (RF) energy** technology to create a new category of treatments: **minimally-invasive** procedures. This technique allows doctors to achieve surgical-like results by working beneath the skin's surface but only through tiny incisions, meaning significantly reduced downtime and no large scars.

#### **II. The Era of Game-Changing Products (2017 - 2020)**

4.  **Major Product Breakthrough (BodyTite):** The launch of the **BodyTite** platform around 2017 established InMode as a pioneer in this new category. This device uses **Radio-Frequency Assisted Lipolysis (RFAL)**, where a small probe is inserted under the skin to both melt fat and simultaneously tighten the skin using RF energy.

5.  **A Powerful Tailwind - Solving the Gap:** BodyTite was a huge tailwind because it gave plastic surgeons and dermatologists a tool to offer patients who wanted noticeable body contouring and skin tightening without committing to major surgery. This directly delivered on the company’s founding mission to bridge the "Treatment Gap."

6.  **Going Public (IPO):** Capitalizing on its growing product success, InMode completed its Initial Public Offering (IPO) in August 2019, which raised significant capital for the company's continued global expansion.

7.  **The Global Blockbuster (Morpheus8):** Around 2020, InMode launched the **Morpheus8** platform, which uses fractional RF microneedling. This became arguably the company’s most popular treatment, famous for improving skin texture, wrinkles, and acne scarring.

8.  **Celebrity Endorsements as a Tailwind:** The popularity of Morpheus8, even gaining endorsement from celebrities like Kim Kardashian, drove immense consumer awareness and demand, helping the brand become one that patients specifically request by name.

#### **III. Headwinds and Strategic Response (2021 - Present)**

9.  **The Business Model Strength:** A major structural tailwind for InMode is its business model, which is built on two revenue streams: the initial sale of its main equipment (the capital equipment) and the **recurring revenue** from disposable handpieces and service contracts required for every procedure. This high-margin revenue (with gross margins consistently around 78-80%) provides financial stability.

10. **Headwind - Macroeconomic Downturn (2024-2025):** Starting in 2024, the company faced a significant headwind due to a global economic slowdown. High inflation and increased interest rates made it harder for medical practices to get loans to buy InMode's expensive equipment, and general consumer uncertainty reduced spending on elective cosmetic procedures, especially in the key North American market.

11. **Strategic Solution - Share Buybacks and Cash Management:** To manage this slowdown and reassure investors, InMode aggressively used its substantial cash reserves for large-scale share repurchase programs. This move demonstrates management's confidence in the company’s long-term value despite the temporary decline in sales growth.

12. **Headwind - Legal and Competitive Issues:** Like many successful public companies, InMode faced competitive pressure and legal challenges, including a securities class action lawsuit filed in early 2024 alleging misleading statements, which the company is actively defending against.

13. **Solution - Continuous Innovation and Diversification:** InMode’s core solution to market challenges is constant innovation. The company continues to launch new platforms, such as **IgniteRF** and **Optimus Max** in 2024, and is strategically expanding its core RF technology beyond cosmetics into new medical fields like **women’s health (EmpowerRF)** and **ophthalmology (Envision)** to diversify its revenue streams and capture new multi-billion dollar markets.

14. **InMode's Goal Today:** Today, InMode is a profitable, cash-rich global leader in the minimally-invasive aesthetic technology space. Its current goal is to weather the economic headwind by leveraging its high-margin consumable model and expanding its technology to become the go-to partner for physicians across numerous specialties, ensuring long-term growth by pioneering innovative, life-changing procedures.

---

## Moat Analysis

The moat of InMode Ltd. (INMD) is best described as a "Narrow Moat," built primarily on its proprietary technology, high customer switching costs, and exceptional financial model.

Here is an analysis of the company's competitive advantages:

### 1. Unique Technology and Product Differentiation (The Reason for Growth)

*   **Minimally Invasive Leadership:** InMode grew by pioneering the middle ground between highly effective but invasive surgery and less effective non-invasive aesthetic treatments.
*   **Proprietary RF Technology:** Its platforms utilize proprietary Radiofrequency (RF) technology to perform minimally invasive procedures that remodel fat, tissue, and skin with less downtime than traditional surgery, providing a significant selling point to doctors and patients.
*   **Product Versatility:** Their workstations can perform multiple different treatments by simply changing the handpiece, which is a key advantage compared to competitors whose machines are often limited to one type of procedure.

### 2. Pricing Power and Market Position

*   **Exceptional Profitability:** InMode consistently maintains high gross margins, which have been around the 80% mark, demonstrating superior manufacturing efficiency and strong pricing power for both its capital equipment and consumables.
*   **Filling a Niche:** The company successfully positioned itself as a leader in the high-growth, energy-based, minimally invasive aesthetic device market.

### 3. Customer Stickiness and Contracts (The Moat's Foundation)

*   **Razor-and-Blade Business Model:** The core of the moat is the "razor-and-blade" model, where the initial sale of the high-priced equipment (the "razor") locks in a source of recurring, high-margin revenue from the single-use disposable handpieces and service contracts (the "blades").
*   **High Switching Costs:** Once a clinic has purchased and integrated an InMode platform, the continued need to buy their exclusive, single-use handpieces for every procedure creates high switching costs, making the customer base sticky.
*   **Recurring Revenue:** While capital equipment sales are currently the majority of revenue, the growing and high-margin consumables and service segment provides a predictable, recurring revenue stream.

### 4. Innovation and Investment in the Moat

*   **R&D and Patents:** The company was founded by an experienced team and is built on consistent innovation, holding a strong portfolio of proprietary patents.
*   **Constant Innovation Required:** As technology in the aesthetic space changes quickly, InMode must constantly invest in research and development and launch new platforms (like the recent expansion into women's health and eye care) to maintain its competitive edge.

### 5. Ease of Displacement

*   **Defensible but Not Impenetrable:** Experts generally rate the company with a "Narrow Moat," meaning it is defensible but could be challenged.
*   **Capital Strength as a Buffer:** InMode has historically maintained a pristine balance sheet, with a significant cash reserve and minimal debt, providing a financial buffer against macroeconomic uncertainty or a well-funded competitor's price war.
*   **Displacement Challenge:** A competitor with more capital would need to develop a technology that is demonstrably better than InMode's patented procedures, overcome the high switching costs of InMode's installed base, and establish a similarly strong clinical reputation.
*   **Network Effects:** The company does not benefit from significant network effects (where the value of the product increases as more people use it) that would make the business nearly impossible to displace.

---

## Catalyst Analysis

The catalysts for InMode Ltd. (INMD) can be divided into near-term factors (resolving current headwinds and immediate strategic actions) and long-term drivers (structural growth and recurring revenue).

---

### Near-Term Catalysts

1.  **Resolution of Macroeconomic Headwinds:** A major catalyst is a decrease in high interest rates and improvement in the macroeconomic environment, which management explicitly noted is affecting capital equipment sales, especially financing and leasing activities. An easing of these conditions is expected to immediately boost sales of new systems.
2.  **Sales Force Reorganization and Geographical Expansion:** Management has initiated structural reorganization and geographical segmentation in North America and management reshuffles in Europe to enhance market penetration. Successfully implementing this restructuring and expanding directly into new markets like Thailand and Argentina should boost short-term sales velocity.
3.  **Share Repurchase Program:** The ongoing execution of the company's share repurchase program provides direct support for the stock price by reducing the number of outstanding shares and returning capital to shareholders.
4.  **Success of New Product Launches:** The immediate market acceptance and sales conversion of recently introduced platforms, such as **IgniteRF** and **Optimus Max**, will drive near-term revenue. Management is focused on the successful commercial rollout of these new innovations.

### Long-Term Catalysts

1.  **Growth of Recurring Revenue (Consumables and Service):** The growing base of installed systems generates a stable, high-margin revenue stream from consumables and service contracts, which management notes is a resilient part of their business and a key growth driver. Continued growth in this segment offers financial stability and less reliance on capital equipment sales.
2.  **Expansion into New Medical Specialties (Wellness):** A core part of management's long-term strategy is launching new platforms to penetrate new markets like the **wellness space** and the **urology community**. This diversifies their product offering beyond traditional aesthetics and opens up significant new markets for sustained growth.
3.  **Strong Balance Sheet and Financial Discipline:** InMode maintains a strong balance sheet with a large cash position (over $684 million as of Q3 2024) and high gross margins, even in a challenging environment. This financial strength allows for continued strategic investments, R&D, and acquisitions without needing external funding, which is a long-term competitive advantage.
4.  **Focus on Minimally Invasive Technology:** The company's core technology is centered on minimally invasive procedures, which management highlights as a significant portion of their revenue (around 87% in Q2 2024). This focus aligns with the long-term trend of patients seeking less invasive procedures that offer comparable results to surgery.

---

## Management Record

The management of InMode Ltd. (INMD) has a deeply rooted history in the aesthetic medical device industry, characterized by stable, long-tenured leadership and a recent strategic pivot to maximize shareholder returns.

### **1. Executive Background and History**

1.  **Founders' Proven Industry Track Record:** Co-founders Moshe Mizrahy (CEO) and Dr. Michael Kreindel (CTO) have a history of success in the sector, having previously co-founded Syneron Medical Ltd., an aesthetic medical device company.
2.  **Long-Tenured and Stable Leadership:** The core management team is highly seasoned, with an average tenure of 13.3 years, and CEO Moshe Mizrahy has served since the company's inception in January 2008, promoting a consistent strategic vision.
3.  **Co-Founders' Ownership:** CEO Moshe Mizrahy directly owns a significant stake in the company, which aligns his personal financial interests with long-term shareholder value creation.

### **2. Performance and Delivery on Promises (Track Record)**

1.  **Strong Historical Growth:** In the years leading up to the recent market slowdown, the management team delivered significant growth, increasing revenue from $206 million to nearly $500 million, representing a 34% Compound Annual Growth Rate (CAGR).
2.  **Recent Revenue Guidance Misses:** Due to "continued market weakness and persistent uncertainty surrounding the U.S. economic outlook," management has had to revise its full-year revenue guidance downward, indicating a challenge in delivering on short-term growth promises.
3.  **Maintaining High Margins:** Despite the recent deceleration in revenue growth, the management team has maintained a highly profitable, asset-light business model with a best-in-class non-GAAP gross margin consistently around 79-80%.

### **3. Key Decisions and Shareholder Value Creation**

1.  **Strategic Shift to Shareholder Returns:** Management has recently made a major pivot in capital allocation strategy by initiating substantial share repurchase programs to return cash to shareholders.
2.  **Significant Share Buybacks:** The company returned over \$280 million to shareholders through share repurchases in 2024 and plans to acquire approximately another 10% of its market value in 2025.
3.  **Investing in North American Leadership:** To address the recent softness in the critical U.S. market, management appointed Michael Dennison as President of North America, aiming to reenergize sales and improve execution in the region.
4.  **Proprietary Technology Focus:** A key decision from the co-founders was to pivot early to developing and commercializing proprietary Radio-Frequency (RF) technology for minimally-invasive procedures, which became the company's core sustainable advantage.

### **4. Future Strategy and Vision**

1.  **Two-Pillar Growth Catalyst:** The central focus of the future strategy is a two-pronged approach: "winning back procedure growth" in the core markets and "accelerating international expansion."
2.  **International Market Reliance:** Management expects international sales to be a primary driver for a future turnaround, with growth outside the U.S. projected to rebound to a high double-digit percentage for 2025.
3.  **Innovation as a Long-Term Driver:** The company's vision includes the launch of new innovative products (likely in 2026+) to re-establish a growth trajectory following the current market headwinds.
4.  **Commitment to Financial Strength:** The current strategy is to maintain a strong balance sheet and high free cash flow generation, which supports the continued return of capital to investors through buybacks and potential extraordinary dividends.

---

## Management Incentive

Based on the analysis of InMode Ltd.'s (INMD) governance documents, including its Form 20-F and other filings, here is an analysis of the management's incentive and compensation structure:

### Management Incentive and Compensation Analysis for InMode Ltd. (INMD)

#### 1. Insider Ownership by Managers and Directors
*   The Chief Executive Officer (CEO), Moshe Mizrahy, has a significant direct ownership stake of approximately **5.54%** of the company's outstanding shares.
*   This substantial personal ownership by the CEO provides a strong incentive for him to act in the best long-term interest of all shareholders, as his personal wealth is directly tied to the company's stock performance (higher the better).
*   The beneficial ownership of other directors and executive officers is generally reported as less than 1% individually, though many hold a mix of ordinary shares, stock options, and Restricted Stock Units (RSUs).

#### 2. Compensation Structure
*   The compensation structure for executive officers includes Base Salary, Benefits, Cash Bonuses, and **Equity-Based Compensation** (such as stock options and RSUs).
*   The policy's objective is to tie the compensation of executive officers and directors to the company's goals and performance, which is a key mechanism for aligning management with shareholder interests.
*   Equity-based compensation is capped such that its fair market value cannot exceed **200% of the executive officer's annual Base Salary**, aiming to maintain a performance-focused pay mix.
*   The company has an updated Compensation Policy that includes expanded **clawback provisions**, allowing the company to recover erroneously awarded performance-based equity compensation, which enhances accountability.

#### 3. Incentive Alignment and Conclusion
*   **Strong Alignment:** The high percentage of shares held by the CEO, combined with a compensation policy that utilizes performance-tied equity grants (options and RSUs), strongly suggests that management is primarily incentivized to enhance shareholder value through stock price appreciation.
*   **Potential Conflict/Oversight:** A potential area of conflict arose when the Compensation Committee and Board re-approved an Updated Compensation Policy—which included a **50% increase** to the maximum annual base salary limits for executive officers—even after it was **not approved by a shareholder vote**, citing authority under the Israeli Companies Law.
*   **Conclusion:** Overall, the **high CEO ownership** and the emphasis on **equity-based, recoverable compensation** indicate that the management has significant incentives to act in the interest of the shareholders, despite the board's decision to bypass the shareholder vote on the salary limit increase.

---

## Price History

Based on recent price history, technical analysis, and company news, here is an analysis of InMode Ltd. (INMD).

### InMode Ltd. (INMD) Stock Analysis

1.  **Proximity to 52-Week Low:** The stock is currently trading very close to its 52-week low. With a recent price around \$14.06 and a 52-week low of \$13.14, the stock is approximately **7.00%** above its 52-week floor.

2.  **Technical Analysis Sentiment:** A technical analysis from TradingView indicates a "Strong Sell" overall rating, with a "Sell" trend prevailing on the 1-month rating, suggesting technical indicators point to continued downward pressure or weak momentum.

3.  **"Trading Low" Status:** From a simple price-range perspective, the stock is trading at the lower end of its 52-week range of \$13.14 to \$19.83, reinforcing the idea that it is technically "low."

4.  **Major Drop Explanation (Last Few Months):** The stock experienced significant drops due to disappointing quarterly financial results and subsequent cuts to its full-year revenue and earnings guidance.

5.  **Q1 and Q2 2025 Sell-Offs:** The stock saw sharp single-day drops (e.g., over 11% and 8.55%) after its Q1 and Q2 2025 earnings reports, as the company's EPS and revenue either missed or came in lower than analyst expectations.

6.  **Underlying Headwinds:** The company cited "continued market weakness and uncertainty in the U.S. economic environment" as the primary reasons for the reduced guidance and performance struggles. This macroeconomic pressure on the medical aesthetics market is a key headwind.

7.  **Valuation Context:** Despite the recent price weakness, some analyses suggest the stock is undervalued, noting an attractive Price-to-Earnings (P/E) ratio and a strong financial health score.

8.  **Long-Term Price History:** The current trading range is significantly lower than its all-time high of \$99.27, which it reached in November 2021, highlighting a massive, multi-year price contraction.

---

## Long Thesis

InMode is a profitable medical device company whose stock is currently priced low because of a temporary economic downturn that is hurting sales of their expensive machines. The bull case rests on two pillars: First, management is aggressively buying back stock using the company’s massive cash reserves, providing direct support to the share price while waiting for the economy to recover. Second, the company’s core long-term strength is its 'razor and blade' business model. Once a clinic purchases an InMode platform, they are locked into buying high-margin disposable tips for every procedure forever. As more machines are installed globally, this recurring revenue stream grows and stabilizes profits. In the long run, InMode is expanding this proven technology beyond traditional cosmetic procedures into massive new fields like women’s health and eye care, which will drive sustainable, diversified growth once the economy improves.

---

## Long Thesis Assumptions

This bull case assumes that the current global economic weakness eases soon, allowing medical practices to resume purchasing expensive capital equipment. It also assumes that InMode's proprietary, minimally-invasive technology remains superior and competitive, preventing rivals from disrupting their high-margin 'razor and blade' model. Finally, the success of their ambitious strategy to enter and capture market share in new medical specialties (like women's health) is crucial for diversifying revenue and maintaining long-term growth above historical levels.

---

## Bear Case Scenario

The long thesis for InMode Ltd. (INMD) has several significant holes and relies on assumptions that are contradicted or challenged by recent financial performance, competitive dynamics, and managerial context.

### **Critique and Flaws in the Bull Case Thesis**

1.  **The "Temporary Economic Downturn" is Prolonged and Significant:**
    The decline in sales of expensive machines is not proving to be "temporary"; full-year 2024 revenue decreased by a substantial 20% compared to the prior year, and management has issued conservative guidance for 2025, suggesting a structural headwind for large capital equipment purchases. This extended weakness suggests high interest rates and cautious spending by clinics are persistent, not just a brief downturn.

2.  **The "Razor and Blade" Model is Showing Cracks and Margin Pressure:**
    While the thesis emphasizes growing recurring revenue, the consumables and service revenue stream has shown volatility, with a 10% decrease in Q1 2025 year-over-year, which contradicts the "stabilizes profits" claim. Furthermore, gross margins, while still high, declined to 78% in Q3 2025 due to the anticipated impact of tariffs, indicating external factors can easily erode the high-margin structure.

3.  **Stock Buyback Effectiveness and Management Credibility are Under Scrutiny:**
    The use of "massive cash reserves" for buybacks is correct, but the strategy is being challenged by an activist investor (DOMA Perpetual Capital) who has criticized the CEO's past comments on the buybacks' effectiveness and urged for a faster, larger repurchase program. This suggests the current buyback pace may be insufficient to provide the necessary support to the share price and introduces internal leadership uncertainty as a factor.

4.  **Superior Technology and Competitive Threat is Overstated:**
    The assumption of continued technological superiority is vulnerable due to the highly competitive landscape. Major rivals like Cynosure, Cutera, Candela, and Alma Lasers are actively deploying multi-application platforms, including non-RF technologies like HIFU and various advanced lasers, which compete directly with InMode's minimally-invasive approach. These competing technologies and platforms offer alternatives to clinics and threaten the long-term defensibility of InMode's high-margin "razor and blade" ecosystem.

5.  **Expansion into New Markets is Unproven Speculation:**
    The future growth reliance on "massive new fields" like women's health and eye care is speculative; while InMode has launched new platforms (like Envision) and acquired IP, the company has not yet provided concrete data on market share capture or significant revenue contribution from these new specialties. This crucial pillar of the long-term growth story is currently an unvalidated assumption for diversification.

***

### **Bear Case Thesis for InMode Ltd. (INMD)**

The "temporary economic downturn" is masking a structural slowdown in InMode’s core business, and the premium valuation commanded by its historically high growth and margins is unsustainable in a highly competitive and contracting market.

1.  **Cyclical Demand Shock is Now Structural:** Capital equipment sales have been significantly and repeatedly hit by high interest rates, leading to conservative purchasing by clinics and a major, prolonged revenue decline (20% in 2024). This indicates a systemic demand issue, not a short-term blip, which is compounded by management giving conservative guidance for the next year.

2.  **"Razor and Blade" Vulnerability:** The high-margin consumables model is vulnerable to competitive erosion from new technologies (e.g., advanced laser, HIFU) that may offer comparable results without InMode’s costly disposable tips, or from competitors simply undercutting pricing. Furthermore, the consumables revenue itself showed a year-over-year decline in Q1 2025, challenging its assumed stability.

3.  **Declining Profitability and Margin Compression:** Operating margins and net income have seen significant declines due to the drop in system sales, and even high gross margins are starting to compress due to external factors like new tariffs. This trend undermines the core argument of superior, stable profitability.

4.  **Ineffective Capital Allocation and Leadership Concerns:** The massive stock buyback program, while reducing share count, has failed to sustainably support the stock price and is subject to activist criticism regarding its sufficiency and management's mixed messaging. This suggests capital could be deployed more effectively in R&D or acquisitions to secure long-term growth, rather than just slowing the share price decline.

5.  **Lack of Proven Diversification:** Growth into new medical specialties (women's health, eye care) is a high-risk, unproven venture without any quantifiable market traction yet. The company's reliance on these new, complex sectors to offset core aesthetic business weakness represents a huge execution risk and is currently only a speculative path for future growth.

---

## Next Steps

Based on the thorough analysis you've completed, the next steps should focus on quantifying the risks and validating the unproven growth pillars to resolve the key conflicts between the bull and bear cases.

Here are the most important questions and investigation steps, using the latest information (which includes Q3 2025 results and activist details):

### **1. Quantify the Resilience of the "Razor and Blade" Model**

*   **Determine the Current Revenue Mix:** Calculate the exact percentage of total revenue that the high-margin consumables and service segment represents based on the most recent financial report (Q3 2025). The search results indicate consumables and service revenue was **$19.9 million**, up $10 \%$ year-over-year, against total revenue of **$93.2 million**. This will clarify the actual reliance on capital equipment sales versus the recurring stream.
*   **Identify the Core Revenue Contraction:** Confirm the breakdown of the $93.2 million in Q3 2025 revenue compared to Q3 2024 (which included a large amount of preorder sales) to determine the *true* drop in capital equipment sales. This is crucial for assessing if the cyclical downturn is bottoming.

### **2. Validate New Growth Verticals (The Diversification Strategy)**

*   **Seek Revenue from New Platforms:** Investigate if management has ever disclosed the revenue contribution from the non-aesthetic platforms like **EmpowerRF** (women's health) and **Envision** (ophthalmology). The search mentioned their launch and importance, but did not give specific sales numbers. The long-term thesis heavily relies on these, so their performance is critical.
*   **Investigate Market Adoption:** Search for independent clinical studies, physician testimonials, or third-party market reports discussing the adoption rate of EmpowerRF and Envision within the respective medical communities (gynecology/urology and ophthalmology).

### **3. Assess Competitive and Intellectual Property (IP) Risk**

*   **Determine Patent Cliff Risk:** Investigate the specific patent portfolio and determine when the key patents for the *Morpheus8* and *BodyTite* platforms are set to expire, not just the general RF technology patent (which is 2035). This is necessary to understand when the "moat" truly degrades.
*   **Identify Threat to Consumables:** Research competitors who have launched or plan to launch advanced energy-based devices that **do not rely on disposables** to see if the "razor and blade" model is facing an imminent existential threat, as the bear case suggests.

### **4. Analyze Leadership, Governance, and Activist Pressure**

*   **Detail Activist Demands and Ouster Call:** Investigate the specific public letters from **DOMA Perpetual Capital** to fully understand their critique, which includes calling for the removal of the CEO, Moshe Mizrahy, and demanding larger/faster buybacks (20% of market cap over two quarters). This adds significant risk to management stability.
*   **Find Management's Official Response:** Search for InMode's official press releases or CEO commentary in response to DOMA Perpetual's latest demands to gauge the likelihood of a proxy fight or a change in capital allocation strategy.

### **5. Financial and Margin Outlook**

*   **Finalize Tariff Impact on Margins:** Confirm the official full-year 2025 guidance for gross margins (expected to be **78% to 80%**) to ensure the margin compression due to tariffs is fully accounted for in the valuation.
*   **Search Analyst Consensus:** Find the current consensus price target and rating (Buy/Hold/Sell) from major analyst firms (e.g., Goldman Sachs, Jefferies) to see if the professional investment community has moved from the "Strong Sell" technical signal mentioned in your price history.